Novel inflammatory biomarkers associated with stroke severity: results from a cross-sectional stroke cohort study.
Biomarkers
Functional outcome
Stroke
Stroke severity
Journal
Neurological research and practice
ISSN: 2524-3489
Titre abrégé: Neurol Res Pract
Pays: England
ID NLM: 101767802
Informations de publication
Date de publication:
20 Jul 2023
20 Jul 2023
Historique:
received:
04
04
2023
accepted:
20
06
2023
medline:
20
7
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
Stroke is a leading cause of mortality and disability worldwide and its occurrence is expected to increase in the future. Blood biomarkers have proven their usefulness in identification and monitoring of the disease. Stroke severity is a major factor for estimation of prognosis and risk of recurrent events, but knowledge on respective blood biomarkers is still scarce. Stroke pathophysiology comprises a multitude of ischemia-induced inflammatory and immune mediated responses. Therefore, the assessment of an immune-related panel in correlation with stroke severity seems promising. In the present cross-sectional evaluation, a set of 92 blood biomarkers of a standardized immune panel were gathered (median 4.6 days after admission) and related to stroke severity measures, assessed at hospital admission of acute stroke patients. Multivariable logistic regression models were used to determine associations between biomarkers and modified Rankin Scale (mRS), linear regression models were used for associations with National Institute of Health Stroke Scale. 415 patients (mean age 69 years; 41% female) were included for biomarker analysis. C-type lectin domain family 4 member G (CLEC4G; OR = 2.89, 95% CI [1.49; 5.59], p Higher relative concentrations of plasma CLEC4G, CKAP4, and IL-6 were associated with higher stroke severity, whereas LY75 and ITGA11 showed an inverse association. Future research might show a possible use as therapeutic targets and application in individual risk assessments.
Sections du résumé
BACKGROUND
BACKGROUND
Stroke is a leading cause of mortality and disability worldwide and its occurrence is expected to increase in the future. Blood biomarkers have proven their usefulness in identification and monitoring of the disease. Stroke severity is a major factor for estimation of prognosis and risk of recurrent events, but knowledge on respective blood biomarkers is still scarce. Stroke pathophysiology comprises a multitude of ischemia-induced inflammatory and immune mediated responses. Therefore, the assessment of an immune-related panel in correlation with stroke severity seems promising.
METHODS
METHODS
In the present cross-sectional evaluation, a set of 92 blood biomarkers of a standardized immune panel were gathered (median 4.6 days after admission) and related to stroke severity measures, assessed at hospital admission of acute stroke patients. Multivariable logistic regression models were used to determine associations between biomarkers and modified Rankin Scale (mRS), linear regression models were used for associations with National Institute of Health Stroke Scale.
RESULTS
RESULTS
415 patients (mean age 69 years; 41% female) were included for biomarker analysis. C-type lectin domain family 4 member G (CLEC4G; OR = 2.89, 95% CI [1.49; 5.59], p
CONCLUSIONS
CONCLUSIONS
Higher relative concentrations of plasma CLEC4G, CKAP4, and IL-6 were associated with higher stroke severity, whereas LY75 and ITGA11 showed an inverse association. Future research might show a possible use as therapeutic targets and application in individual risk assessments.
Identifiants
pubmed: 37468969
doi: 10.1186/s42466-023-00259-3
pii: 10.1186/s42466-023-00259-3
pmc: PMC10357843
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31Informations de copyright
© 2023. The Author(s).
Références
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
Stroke. 1995 Aug;26(8):1393-8
pubmed: 7631343
Genomics. 2014 Sep;104(3):163-9
pubmed: 25135788
Clin Neurol Neurosurg. 2020 Aug;195:105892
pubmed: 32416324
Crit Care. 2013 Mar 16;17(2):R45
pubmed: 23497639
Neurology. 2015 Jul 28;85(4):373-80
pubmed: 26136519
JAMA Neurol. 2021 Mar 1;78(3):321-328
pubmed: 33427887
Front Neurol. 2019 Aug 21;10:910
pubmed: 31496988
Stroke. 2020 Dec;51(12):3541-3551
pubmed: 33040701
Int J Toxicol. 2017 Mar/Apr;36(2):153-164
pubmed: 28056587
Mol Cell Proteomics. 2021;20:100168
pubmed: 34715355
Immunogenetics. 1998 May;47(6):442-50
pubmed: 9553150
Stroke. 2019 May;50(5):1263-1265
pubmed: 30890116
Stroke. 2017 Apr;48(4):1011-1019
pubmed: 28280137
Front Neurol. 2021 Dec 06;12:734345
pubmed: 34938254
Neurol Sci. 2022 Feb;43(2):1155-1166
pubmed: 34313877
Stroke. 1999 May;30(5):981-5
pubmed: 10229731
Virology. 2005 Sep 30;340(2):224-36
pubmed: 16051304
J Neurol Sci. 2017 Aug 15;379:229-235
pubmed: 28716248
J Vet Med Sci. 2012 Oct;74(10):1363-6
pubmed: 22673088
Clin Pharmacol Ther. 2021 Oct;110(4):1038-1049
pubmed: 34048027
Int J Med Inform. 2019 Dec;132:103986
pubmed: 31629312
Eur J Neurol. 2022 Nov;29(11):3288-3295
pubmed: 35836373
Arch Virol. 2014 Aug;159(8):2023-31
pubmed: 24623090
Stroke. 2001 Jan;32(1):199-205
pubmed: 11136937
Int J Cardiovasc Imaging. 2021 Apr;37(4):1171-1187
pubmed: 33184741
Gastroenterology. 2009 Oct;137(4):1498-508.e1-5
pubmed: 19632227
J Neurointerv Surg. 2022 Mar;14(3):248-251
pubmed: 33883212
J Virol. 2012 Feb;86(4):2067-78
pubmed: 22156524
J Stroke Cerebrovasc Dis. 2021 Aug;30(8):105935
pubmed: 34153594
Iran J Neurol. 2014 Apr 3;13(2):70-6
pubmed: 25295149
Eur Psychiatry. 2020 Nov 16;63(1):e97
pubmed: 33190666
Medicina (Kaunas). 2020 Jun 06;56(6):
pubmed: 32517235
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846